iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump

• Status: Not yet recruiting
• Trial end date: 2023-11-30
• Target enrollment: 0
• Participant gender: All

Summary

Introduction: Diabetes Mellitus (DM) is a condition known to be associated with coronary artery disease (CAD) and its role as promoter of atherosclerosis is well stablished. The revascularization surgery is commonly indicated to patients with multivessel coronary disease and kidney injury is a prevalent complication in post operation. This work aims to evaluate the impact of a strategy to control Diabetes Mellitus using inhibitors of sodium-glucose cotransporters (ISGLT2) in diabetics patients with assigned myocardial revascularization with cardiopulmonary bypass

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo General Hospital
• Treatments: Empagliflozin

Criteria

Inclusion Criteria:

• Age > 18

• Type 2 diabetes mellitus

• Multivessel CAD documented by coronary angiography with formal indication for CRM.

Exclusion Criteria:

• eGFR <30mL / min / 1.73m2 or dialysis therapy;

• Inability to sign the informed consent form;

• Contraindication to CABG on pump;

• Need for urgent or emergency CABG;

• Terminal or disabling illness with reduced life expectancy;

• Pregnancy in progress.